Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.L. Álvarez-Sala, E. Cimas, J.F. Masa, M. Miravitlles, J. Molina, K. Naberan, et al.
Recomendaciones para la atención al paciente con enfermedad pulmonar obstructiva crónica. SemFYC-SEPAR.
Arch Bronconeumol, 37 (2001), pp. 269-278
[2.]
E. Calvo, E. Cimas, E. Hernández, M.A. Llauguer, J. Molina.
Naberan KX y grupo de Respiratorio de semFYC. EPOC. En: Programas Básicos de Salud. Programa del Adulto. Madrid: Ed.
Doyma, (1999),
[3.]
R. Vidal Plá, J.L. Alvarez-Sala Walther, J.E. García Sánchez, J.F. Masa Jiménez, M. Miravitlles Fernández, J. Molina París, et al.
EPOC: clasificación y estrategias. Conclusiones de un Grupo de Trabajo Multidisciplinar.
[4.]
V. Sobradillo, M. Miravitlles, C.A. Jiménez, R. Gabriel, J.L. Viejo, J.F. Masa.
Estudio IBERPOC en España: prevalencia de síntomas respiratorios habituales y de limitación crónica al flujo aéreo.
Arch Bronconeumol, 35 (1999), pp. 159-166
[5.]
R.A. Pauwels, A.S. Buist, P.M.A. Calverley, C.R. Jenkins, S.S. Hurd.
Global strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease. National Heart, Lung and Blood Institute/WHO. Global Initiative for Obstructive Lung Disease (GOLD), Workshop Summary.
Am J Respir Crit Care Med, 163 (2001), pp. 1256-1276
[6.]
C. Fletcher, R. Peto, C. Tinker, F.E. Speizer.
The natural history of chronic bronchitis and emphysema.
[7.]
R.D. Hurt, D.P.L. Sachs, E.D. Glover, K.P. Offord, J.A. Johnston, P.D. Lowell, et al.
A comparison of sustained-release bupropion and placebo for smoking cessation.
N Engl J Med, 337 (1997), pp. 1195-1202
[8.]
The COPD Guidelines Group of the Standard of Care Committee of the British Thoracic Society (BTS).
BTS Guidelines for the Management of Chronic Obstructive Pulmonary Disease.
Thorax, 52 (1997), pp. S1-S28
[9.]
R. Wood-Baker, E.H. Walters.
Corticosteroids for acute exacerbations of chronic obstructive pulmonary disease (Cochrane Review). En: The Cochrane Library, Issue 1.
[10.]
D.E. Niewoehner, M.L. Erbland, R.H. Deupree, D. Collins, N.J. Gross, R.W. Light, et al.
Effects of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease.
N Engl J Med, 340 (1999), pp. 1941-1947
[11.]
P.S. Burge.
EUROSCOP, ISOLDE and the Copenhagen city lung study.
Thorax, 54 (1999), pp. 287-288
[12.]
R.A. Pauwels, C.G. Löfdahl, L.A. Laitinen, J.P. Schouten, D.S. Postma, N.B. Pride, et al.
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking.
N Engl J Med, 340 (1999), pp. 1948-1953
[13.]
P.S. Burge, P.M.A. Calverley, P.W. Jones, S. Spencer, J.A. Anderson, T.K. Maslen.
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.
BMJ, 320 (2000), pp. 1297-1303
[14.]
P.J. Poole, P.N. Black.
Mucolytic agents for chronic bronchitis (Cochrane Review). En: The Cochrane Library, Issue 1.
[15.]
R. Zalacaín.
Infección y enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol, 34 (1998), pp. 453-456
[16.]
N.R. Anthonisen, J. Manfreda, C.P.W. Warren, E.S. Hershfield, G.K. Harding, N.A. Nelson.
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.
Ann Intern Med, 106 (1987), pp. 196-204
[17.]
P. De Lucas, R. Güel, V. Sobradillo, C.A. Jiménez, M. Sangenis, T. Montemayor, et al.
Normativa sobre la rehabilitación respiratoria.
Arch Bronconeumol, 36 (2000), pp. 257-274
[18.]
J. Ancoechea, R.M. Girón.
Abordajes terapéuticos más selectivos y eficientes. Tiotropio: repercusiones en el manejo futuro del paciente con EPOC.
Arch Bronconeumol, 37 (2001), pp. 43-47
[19.]
P.J. Barnes, M.G. Belvisi, J.C.W. Mak.
Tiotropium bromide, (Ba 679 Br), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease.
Life Sci, 56 (1995), pp. 853-859
[20.]
T.J. Witek, J.F. Souhrada, C.W. Serby.
Tiotropium (Ba 679 Br): pharmacology and early clinical observations.
Anticholinergic agents in the upper and lower airways, pp. 137-152
[21.]
F.P.V. Maesen, J.J. Smeets, T.J.H. Sledsens, F.D.M. Wald, P.J.G. Cornelissen.
on behalf of a Dutch study group. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD).
Eur Respir J, 8 (1995), pp. 1506-1513
[22.]
M.R. Littner, J.S. Ilowite, D.P. Tashkin.
Long-acting bronchodilatation with once daily dosing of Tiotropium (Spiriva) in stable COPD.
Am J Respir Crit Care Med, 161 (2000), pp. 1136-1142
[23.]
J.A. Van Noord, T.A. Bantje, M.E. Eland, L. Korduchi, P.J.G. Cornelissen.
on behalf of a Dutch study group. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic pulmonary disease.
Thorax, 55 (2000), pp. 289-294
Copyright © 2003. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)
